Company: MBIO
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001410578-25-000028
Chunk: 244

Company: MUSTANG BIO, INC.
Filing Date: 2025-01-15
Form: S-1
Chunk 244
---
 For the years ended December 31, 2023 and 2022, the Company recorded $ 44,000and $ 0.1million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement. In May 2023, the Company terminated the PSCA License and associated Clinical Research Support Agreement. Fred Hutch CD20 Clinical Trial Agreement On July 3, 2017, in conjunction with the CD20 Technology License from Fred Hutch, we entered into an investigator-initiated clinical trial agreement (“CD20 CTA”) to provide partial funding for a Phase 1/2 clinical trial at Fred Hutch evaluating the safety and efficacy of the CD20 Technology in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. In connection with the CD20 CTA, the Company agreed to fund up to $ 5.3million of costs associated with the clinical trial, which commenced during the fourth quarter of 2017. In November 2020, the CD20 CTA was amended to include additional funding of approximately $ 1.8million for the treatment of five patients with chronic lymphocytic leukemia and other research costs. In January 2022, the CD20 CTA was amended to include additional funding of $ 2.2million increasing the total payment obligation of the Company in connection with the CD20 CTA not to exceed $ 9.3million. For the years ended December 31, 2023 and 2022, the Company recorded $ 1.3million and $ 2.0million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement. St. Jude - XSCID (MB-117) Data Transfer Agreement In June 2020, the Company entered into a Data Transfer Agreement with St. Jude under which we will reimburse St. Jude for costs associated with St. Jude’s clinical trial for the treatment of infants with XSCID. Pursuant to the terms of this agreement the Company paid an upfront fee of $ 1.1million in July 2020, and will continue to reimburse St. Jude for costs incurred in connection with this clinical trial. For the years ended December 31, 2023 and 2022, the Company recorded $ 0.6million and $ 0.5million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement. LUMC - RAG